前列腺癌MDR－PGP170与突变P53表达

Expression of MDR-PGP170 and mutant P53 in prostatic carcinoma

应用单克隆抗体（ＭＤＲ－Ｃ２１９、ＰＡｂ－ＤＯ－１）免疫组化技术对３８例石蜡包埋的前列腺癌与１５例良性前列腺增生（ＢＰＨ）组织切片中的ＭＤＲ－ＰＧＰ与突变Ｐ５３的表达进行了比较研究。结果显示：在３８例前列腺癌切片中ＭＤＲ－ＰＧＰ与突变Ｐ５３蛋白的阳性表达率为７１．０％和６０．５％，１５例ＢＰＨ组织中仅３例（２０．０％）显示ＭＤＲ－ＰＧＰ阳性染色，突变Ｐ５３在所有ＢＰＨ中未见阳性染色。在高分化、中等分化和低分化前列腺癌中ＭＤＲ－ＰＧＰ的阳性表达率为５３．８％、７８．５％和８１．１％。突变Ｐ５３的阳性表达率为３０．８％、７１．４％和７２．７％。结果提示：（１）ＭＤＲ－ＰＧＰ的过度表达是前列腺癌产生抗药的主要机制；（２）ＭＤＲ－ＰＧＰ与突变Ｐ５３的过度表达可能是前列腺癌细胞适存、转化、增殖与进展的重要方式；（３）突变Ｐ５３的过度表达对ＭＤＲ－１基因可能具有调节与增强效应。

Immunohistochemical technique with monoclonal antibody MDR-C219 and Pab-DO-I was used to investigate the expression rates of MDR-PGP170 and mutant P53 tumor suppressor genes in paraffin embeded tissues of 38 cases of prostatic cancer and 15 cases of BPH.The positive expression rates of MDR-PGP170 and mutant P53 were 71.0%(27/38)and 60.5%(23/38)respectively,being strongly stained in 51.8%(14/27)and 29.1%(7/23).In 15 cases of BPH, only 3(20%)revealed positive stain of MDR-PGP170 in mucosal epithelium of prostatic urethra and in prostate glandular epithelium.None of the BPH cases had positive mutant P53 immuno-staining.The positive expression rate of MDR-PGP170 was 53.8%(7/13)in the well-diffrentiated tumors,78.0%(11/14)in the moderately differentiated and 81.0%(9/11)in the poorly differentiated prostatic carcinoma.The respective mutant P53 expression rates wre 38.7%(5/13),71.4%(10/14)and 72.7%(8/11).The results demonstrated that the over-expression of MDR-PGP170 might play an important role in maltidrug resistance of prostatic cancer patients and the over expression of both MDR-PGP170 and mutant P53 might be important factors in the adaptive surviving,transformation,multiplication and progression of prostatic carcinoma cells in vivo.The positive correlative changes of MDR-PGP170 and mutant P53 supports the phenomenon of regulating effect of P53 on MDR-PGP170 expression.